Presentation Type: Poster
Abstract: Breast cancer as the second most common cancer is considered a major problem among women. Presentation of novel therapeutic agents, combinations of existing therapies and targeted therapies have been created a promising future to improve and extend survival of patients. Cancer related antigens express in high amounts and their expression levels are associated with signal transduction cascades that they are related to cancer phenotype. So; membrane antigens are an important target to treat cancer that Her2 receptor used in the aim of treatment. Among the factors that targeted the Her receptor, tyrosine inhibitors and monoclonal antibodies have been attracted great attention. Monoclonal antibodies have still limitations. Nanobodies are the second generation of therapeutic agents that can be ideal because they show small molecules and monoclonal antibodies abilities together. Small size and nature of their single domain give them pharmacological and biophysical properties. A very interesting concept in molecular cancer treatment is based on Polyclonal or oligoclonal antibodies. oligoclonal antibodies target the several epitopes of special antigen and seem to be much more effective than the single monoclonal antibodies. Our aim of this study is evaluating of oligoclonal nanobodies specificity in related to HER2 receptor, their effects on cell signaling pathways in-vitro. Expression of phosphorylation of MAPK, Akt and the total expression of MAPK, Akt are investigated by performing western blots for comparison of downstream signaling pathways of nanobody/HER2 and Herceptin/HER2. Preparing for western blot experiments, cells treated with Herceptin and Nanobodies. In BT-474 cells, Herceptin decreased active AKT, p-MAPK42 and p-MAPK44 and oligoclonal decreased p-MAPK42, p-MAPK44, AKT in compared with the untreated cells as measured by antibodies specific to each pathways. In skbr3 cells, Herceptin decreased MAPK44, p-MAPK42 and Oligoclonal decreased AKT, MAPK44, p-MAPK42 and p-MAPK44 in compared with the untreated cells as measured by antibodies specific to each pathways.